Tag: orphan diseases

February 27, 2017 Off

argenx and Shire extend partnership to fight rare diseases

Argenx and Shire have extended their strategic partnership from 2014 to advance the discovery and development of novel human therapeutic antibodies for diverse rare and unmet diseases for a further year until May 30, 2018.

February 8, 2017 Off

Onxeo clarifies its liver cancer study information

By Dino Mustafić

Onxeo, a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, issued press release to clarify information regarding the Relive trial design and conduct and, in particular, the role of its Data Safety and Monitoring Board (DSMB).